Foreign groups in China are being restricted from transferring their research data abroad, hampering international scientific collaboration and hitting pharmaceutical companies the hardest, according to China-based lawyers.
A regulation passed in March by the State Council, China’s cabinet, mandates that foreign scientists and foreign-invested institutions in China must seek government approval before scientific data can be transferred abroad or to foreign parties within its borders.
In the months since, foreign companies have been scrambling to determine whether this will jeopardise their research investments in China.
您已閱讀17%（625字），剩余83%（3133字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。